Supernus Q1: Qelbree sales +75% to $45.1M; SPN-830 gets FDA CRL; FY guidance reiterated

SUPERNUS PHARMACEUTICALS, INC.

2024-Q1 EPS reported $0.00 revenue$143,644,000

Total revenue of $143.6M; Qelbree net sales surged 75% YoY to $45.1M (IQVIA Rx +31%).
Operating loss of $(3.2)M; adjusted operating earnings (non-GAAP) of $22.3M.
Full-year 2024 guidance reaffirmed: total revenue $580M-$620M, adjusted op. earnings $80M-$110M.
FDA issued Complete Response Letter for SPN-830 (apomorphine infusion) in Parkinson's; resubmission after May 2024 FDA meeting.
SPN-820 Phase IIb >50% enrolled; topline data H1 2025. SPN-817 interim data call May 23; SPN-443 Phase I planned.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SUPERNUS PHARMACEUTICALS, INC. updated its the first quarter of 2024 guidance (reaffirmed).

Period: the first quarter of 2024
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On May 8, 2024, Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") issued a press release regarding its financial results for the first quarter ended March 31, 2024.

View on SEC.gov

1341 earnings releases filed in the last 30 days. Browse all earnings releases →

SUPERNUS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001356576-24-000026

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.